With CTLA-4 Antibody Deal, BioNTech Comes Face-to-Face with BMS’ Yervoy

BioNTech inked an exclusive worldwide license and collaboration agreement with OncoC4 to develop and commercialize its investigational anti-CTLA-4 antibody ONC-392 for solid tumors.